Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Interaction between obesity and the NFKB1 - 94ins/delATTG promoter polymorphism in relation to incident acute coronary syndrome: a follow up study in three independent cohorts.

Stegger JG, Schmidt EB, Berentzen TL, Tjønneland A, Vogel U, Rimm E, Sørensen TI, Overvad K, Jensen MK.

PLoS One. 2013 May 9;8(5):e63004. doi: 10.1371/journal.pone.0063004. Print 2013.

PMID:
23671649
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis.

Zou YF, Wang F, Feng XL, Tao JH, Zhu JM, Pan FM, Su H.

Tissue Antigens. 2011 Jan;77(1):9-17. doi: 10.1111/j.1399-0039.2010.01559.x. Epub 2010 Sep 6.

PMID:
21155719
[PubMed - indexed for MEDLINE]
3.

Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in northwest Spain.

Martin J, Perez-Armengol C, Miranda-Filloy JA, Vilchez JR, Lopez-Nevot MA, Garcia-Porrua C, Gonzalez-Gay MA.

J Rheumatol. 2006 Feb;33(2):285-8.

PMID:
16465659
[PubMed - indexed for MEDLINE]
4.

Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease.

Rueda B, Núñez C, López-Nevot MA, Paz Ruiz M, Urcelay E, De la Concha EG, Martín J.

Scand J Gastroenterol. 2006 Apr;41(4):420-3.

PMID:
16635909
[PubMed - indexed for MEDLINE]
5.

Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis.

Zou YF, Yuan FL, Feng XL, Tao JH, Ding N, Pan FM, Wang F.

Cancer Invest. 2011 Jan;29(1):78-85. doi: 10.3109/07357907.2010.535054.

PMID:
21166501
[PubMed - indexed for MEDLINE]
6.

The NFKB1 ATTG ins/del polymorphism and risk of coronary heart disease in three independent populations.

Vogel U, Jensen MK, Due KM, Rimm EB, Wallin H, Nielsen MR, Pedersen AP, Tjønneland A, Overvad K.

Atherosclerosis. 2011 Nov;219(1):200-4. doi: 10.1016/j.atherosclerosis.2011.06.018. Epub 2011 Jun 17.

PMID:
21726863
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia.

Riemann K, Becker L, Struwe H, Nückel H, Dührsen U, Alakus H, Winde G, Neuhäuser M, Rübben H, Schmitz KJ, Wohlschlaeger J, Schmid KW, Siffert W.

Pharmacogenet Genomics. 2006 Nov;16(11):783-8.

PMID:
17047486
[PubMed - indexed for MEDLINE]
8.

Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes.

Glas J, Török HP, Tonenchi L, Müller-Myhsok B, Mussack T, Wetzke M, Klein W, Epplen JT, Griga T, Schiemann U, Lohse P, Seiderer J, Schnitzler F, Brand S, Ochsenkühn T, Folwaczny M, Folwaczny C.

Inflamm Bowel Dis. 2006 Jul;12(7):606-11.

PMID:
16804398
[PubMed - indexed for MEDLINE]
9.

Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers.

Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS.

Cancer Lett. 2006 Nov 8;243(1):47-54. Epub 2006 Jan 4.

PMID:
16387424
[PubMed - indexed for MEDLINE]
10.

Risk association between the NF-κB1 -94ins/delATTG promoter polymorphism and inflammatory bowel diseases: a meta-analysis.

Liang M, Xu X, Gong Y, Tang Y, Lin L.

Dig Dis Sci. 2012 Sep;57(9):2304-9. doi: 10.1007/s10620-012-2164-x. Epub 2012 Jul 25.

PMID:
22828805
[PubMed - indexed for MEDLINE]
11.

Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus.

Orozco G, Sánchez E, Collado MD, López-Nevot MA, Paco L, García A, Jiménez-Alonso J, Martín J.

Tissue Antigens. 2005 Feb;65(2):183-6.

PMID:
15713218
[PubMed - indexed for MEDLINE]
12.

The NFKB1 promoter polymorphism (-94ins/delATTG) alters nuclear translocation of NF-κB1 in monocytes after lipopolysaccharide stimulation and is associated with increased mortality in sepsis.

Adamzik M, Schäfer S, Frey UH, Becker A, Kreuzer M, Winning S, Frede S, Steinmann J, Fandrey J, Zacharowski K, Siffert W, Peters J, Hartmann M.

Anesthesiology. 2013 Jan;118(1):123-33. doi: 10.1097/ALN.0b013e318277a652.

PMID:
23249930
[PubMed - indexed for MEDLINE]
13.

A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.

Vangsted AJ, Klausen TW, Gimsing P, Andersen NF, Abildgaard N, Gregersen H, Vogel U.

Haematologica. 2009 Sep;94(9):1274-81. doi: 10.3324/haematol.2008.004572.

PMID:
19734419
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis.

Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR.

Hum Mol Genet. 2004 Jan 1;13(1):35-45. Epub 2003 Nov 12.

PMID:
14613970
[PubMed - indexed for MEDLINE]
Free Article
15.

A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population.

Oliver J, Gómez-García M, Paco L, López-Nevot MA, Piñero A, Correro F, Martín L, Brieva JA, Nieto A, Martín J.

Inflamm Bowel Dis. 2005 Jun;11(6):576-9.

PMID:
15905705
[PubMed - indexed for MEDLINE]
16.

NFKB1-94ins/del polymorphism is not associated with lung injury after cardiopulmonary bypass.

Wang JF, Bian JJ, Wan XJ, Zhu KM, Sun ZZ, Lu AD.

Anaesthesia. 2010 Feb;65(2):158-62. doi: 10.1111/j.1365-2044.2009.06186.x. Epub 2009 Nov 25.

PMID:
19995347
[PubMed - indexed for MEDLINE]
17.

No association of the NF-kappaB1 -94ins/delATTG promoter polymorphism with relapse-free and overall survival in patients with squamous cell carcinomas of the head and neck region.

Lehnerdt GF, Bankfalvi A, Grehl S, Adamzik M, Lang S, Schmid KW, Siffert W, Riemann K.

Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):827-32.

PMID:
19144268
[PubMed - indexed for MEDLINE]
18.

Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer.

Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W.

Int J Clin Pharmacol Ther. 2007 Aug;45(8):423-30.

PMID:
17725175
[PubMed - indexed for MEDLINE]
19.

Insertion/deletion polymorphism in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome.

Adamzik M, Frey UH, Rieman K, Sixt S, Beiderlinden M, Siffert W, Peters J.

Intensive Care Med. 2007 Jul;33(7):1199-203. Epub 2007 Apr 28.

PMID:
17468848
[PubMed - indexed for MEDLINE]
20.

Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients.

Lo SS, Chen JH, Wu CW, Lui WY.

Surgery. 2009 Mar;145(3):280-5. doi: 10.1016/j.surg.2008.11.001.

PMID:
19231580
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk